CA3223555A1 - Procede d'obtention rapide de concentrations therapeutiques de zolmitriptan pour le traitement de migraines et de cephalees de horton - Google Patents
Procede d'obtention rapide de concentrations therapeutiques de zolmitriptan pour le traitement de migraines et de cephalees de hortonInfo
- Publication number
- CA3223555A1 CA3223555A1 CA3223555A CA3223555A CA3223555A1 CA 3223555 A1 CA3223555 A1 CA 3223555A1 CA 3223555 A CA3223555 A CA 3223555A CA 3223555 A CA3223555 A CA 3223555A CA 3223555 A1 CA3223555 A1 CA 3223555A1
- Authority
- CA
- Canada
- Prior art keywords
- zolmitriptan
- microns
- microprojections
- patch
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960001360 zolmitriptan Drugs 0.000 title claims abstract description 383
- 238000000034 method Methods 0.000 title claims abstract description 84
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 title claims abstract 6
- 238000011282 treatment Methods 0.000 title abstract description 122
- 208000019695 Migraine disease Diseases 0.000 title abstract description 80
- 230000001225 therapeutic effect Effects 0.000 title abstract description 9
- 208000006561 Cluster Headache Diseases 0.000 title description 58
- 238000000576 coating method Methods 0.000 claims description 130
- 239000011248 coating agent Substances 0.000 claims description 121
- 210000003491 skin Anatomy 0.000 claims description 100
- 239000010936 titanium Substances 0.000 claims description 43
- 239000013543 active substance Substances 0.000 claims description 40
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 30
- 230000036470 plasma concentration Effects 0.000 claims description 29
- 229910052719 titanium Inorganic materials 0.000 claims description 29
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 26
- 210000002381 plasma Anatomy 0.000 claims description 26
- 235000002906 tartaric acid Nutrition 0.000 claims description 26
- 239000011975 tartaric acid Substances 0.000 claims description 25
- 210000000434 stratum corneum Anatomy 0.000 claims description 23
- 239000007787 solid Substances 0.000 claims description 22
- 239000000758 substrate Substances 0.000 claims description 20
- 230000035515 penetration Effects 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 10
- 238000005452 bending Methods 0.000 claims description 6
- 239000003623 enhancer Substances 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 239000005414 inactive ingredient Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000037368 penetrate the skin Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 78
- 206010027599 migraine Diseases 0.000 abstract description 66
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 abstract description 38
- ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 description 358
- 208000002193 Pain Diseases 0.000 description 125
- 230000036407 pain Effects 0.000 description 125
- 239000003814 drug Substances 0.000 description 99
- 229940079593 drug Drugs 0.000 description 90
- 239000003826 tablet Substances 0.000 description 82
- 238000009472 formulation Methods 0.000 description 66
- 239000008199 coating composition Substances 0.000 description 49
- 239000003795 chemical substances by application Substances 0.000 description 43
- 238000010521 absorption reaction Methods 0.000 description 41
- 208000018912 cluster headache syndrome Diseases 0.000 description 38
- QGGCHSMZXKNGCK-GFCCVEGCSA-N N-Desmethylzolmitriptan Chemical compound C1=C2C(CCNC)=CNC2=CC=C1C[C@@H]1COC(=O)N1 QGGCHSMZXKNGCK-GFCCVEGCSA-N 0.000 description 37
- 208000024891 symptom Diseases 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 239000012071 phase Substances 0.000 description 30
- 229960003708 sumatriptan Drugs 0.000 description 29
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 29
- 229910001868 water Inorganic materials 0.000 description 28
- 239000000523 sample Substances 0.000 description 26
- 239000007788 liquid Substances 0.000 description 25
- 239000000902 placebo Substances 0.000 description 25
- 229940068196 placebo Drugs 0.000 description 24
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 23
- 239000000853 adhesive Substances 0.000 description 23
- 230000001070 adhesive effect Effects 0.000 description 22
- 239000002274 desiccant Substances 0.000 description 22
- 238000004806 packaging method and process Methods 0.000 description 21
- 230000005855 radiation Effects 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 206010028813 Nausea Diseases 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 19
- 230000008693 nausea Effects 0.000 description 19
- 239000002207 metabolite Substances 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 18
- 239000012298 atmosphere Substances 0.000 description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 17
- 238000007920 subcutaneous administration Methods 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 239000011888 foil Substances 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 206010019233 Headaches Diseases 0.000 description 14
- 238000012377 drug delivery Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 231100000869 headache Toxicity 0.000 description 14
- 238000003860 storage Methods 0.000 description 14
- 238000004090 dissolution Methods 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 206010054956 Phonophobia Diseases 0.000 description 11
- 206010034960 Photophobia Diseases 0.000 description 11
- 238000009792 diffusion process Methods 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 238000013461 design Methods 0.000 description 10
- 239000013583 drug formulation Substances 0.000 description 10
- 239000012669 liquid formulation Substances 0.000 description 10
- 230000036961 partial effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 206010015150 Erythema Diseases 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000004907 flux Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 230000002411 adverse Effects 0.000 description 8
- 238000003491 array Methods 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 230000008030 elimination Effects 0.000 description 8
- 238000003379 elimination reaction Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000000825 pharmaceutical preparation Substances 0.000 description 8
- 229960000425 rizatriptan Drugs 0.000 description 8
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 8
- 230000037317 transdermal delivery Effects 0.000 description 8
- 206010047700 Vomiting Diseases 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000001647 drug administration Methods 0.000 description 7
- 239000011261 inert gas Substances 0.000 description 7
- 230000036512 infertility Effects 0.000 description 7
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 238000007789 sealing Methods 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 6
- 238000002441 X-ray diffraction Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000005520 cutting process Methods 0.000 description 6
- 229940126534 drug product Drugs 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000011976 maleic acid Substances 0.000 description 6
- 229960005254 naratriptan Drugs 0.000 description 6
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 229940068977 polysorbate 20 Drugs 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 229940102192 zolmitriptan 2.5 mg Drugs 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 238000010579 first pass effect Methods 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000007922 nasal spray Substances 0.000 description 5
- 239000007935 oral tablet Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 4
- 208000034656 Contusions Diseases 0.000 description 4
- 239000004696 Poly ether ether ketone Substances 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 229960002472 eletriptan Drugs 0.000 description 4
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 229960002284 frovatriptan Drugs 0.000 description 4
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 229940096978 oral tablet Drugs 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000004417 polycarbonate Substances 0.000 description 4
- 229920000515 polycarbonate Polymers 0.000 description 4
- 229920002530 polyetherether ketone Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000007761 roller coating Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000036572 transepidermal water loss Effects 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010027603 Migraine headaches Diseases 0.000 description 3
- 206010034912 Phobia Diseases 0.000 description 3
- 208000036071 Rhinorrhea Diseases 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012864 cross contamination Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 206010052787 migraine without aura Diseases 0.000 description 3
- 229940097496 nasal spray Drugs 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 3
- 239000006191 orally-disintegrating tablet Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 208000019899 phobic disease Diseases 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- -1 zolmitriptan Chemical compound 0.000 description 3
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 2
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 2
- 206010003051 Application site pain Diseases 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010021518 Impaired gastric emptying Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 206010033546 Pallor Diseases 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 241000209149 Zea Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229960002133 almotriptan Drugs 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000012080 ambient air Substances 0.000 description 2
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 2
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940090047 auto-injector Drugs 0.000 description 2
- WRZVGHXUPBWIOO-UHFFFAOYSA-N avitriptan Chemical compound C12=CC(CS(=O)(=O)NC)=CC=C2NC=C1CCCN(CC1)CCN1C1=NC=NC=C1OC WRZVGHXUPBWIOO-UHFFFAOYSA-N 0.000 description 2
- 229950002360 avitriptan Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000003618 dip coating Methods 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- SOHCKWZVTCTQBG-UHFFFAOYSA-N donitriptan Chemical compound C1=C2C(CCN)=CNC2=CC=C1OCC(=O)N(CC1)CCN1C1=CC=C(C#N)C=C1 SOHCKWZVTCTQBG-UHFFFAOYSA-N 0.000 description 2
- 229950010344 donitriptan Drugs 0.000 description 2
- 239000013069 drug device combination product Substances 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 208000001288 gastroparesis Diseases 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 235000019837 monoammonium phosphate Nutrition 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229940003675 zomig Drugs 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 description 1
- BWLBGMIXKSTLSX-UHFFFAOYSA-M 2-hydroxyisobutyrate Chemical compound CC(C)(O)C([O-])=O BWLBGMIXKSTLSX-UHFFFAOYSA-M 0.000 description 1
- DBXBTMSZEOQQDU-UHFFFAOYSA-N 3-hydroxyisobutyric acid Chemical compound OCC(C)C(O)=O DBXBTMSZEOQQDU-UHFFFAOYSA-N 0.000 description 1
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 1
- 101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 description 1
- GGZZISOUXJHYOY-UHFFFAOYSA-N 8-amino-4-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C(N)=CC=CC2=C1O GGZZISOUXJHYOY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010050114 Application site bruise Diseases 0.000 description 1
- 206010059005 Application site discolouration Diseases 0.000 description 1
- 206010003041 Application site erythema Diseases 0.000 description 1
- 206010072694 Application site haemorrhage Diseases 0.000 description 1
- 206010003050 Application site oedema Diseases 0.000 description 1
- 206010053424 Application site swelling Diseases 0.000 description 1
- 241001463143 Auca Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 101100504320 Caenorhabditis elegans mcp-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 206010056465 Food craving Diseases 0.000 description 1
- 206010016948 Food interaction Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 101150050738 HTR1B gene Proteins 0.000 description 1
- 208000027109 Headache disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 230000005483 Hooke's law Effects 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000210648 Luciobarbus esocinus Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000000060 Migraine with aura Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000003486 chemical etching Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940018560 citraconate Drugs 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- XFTRTWQBIOMVPK-UHFFFAOYSA-L citramalate(2-) Chemical compound [O-]C(=O)C(O)(C)CC([O-])=O XFTRTWQBIOMVPK-UHFFFAOYSA-L 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000773 effect on pain Effects 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 201000004356 excessive tearing Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000007542 hardness measurement Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000000318 high-performance liquid chromatography-electrospray ionisation tandem mass spectrometry Methods 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical compound OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HNEGQIOMVPPMNR-NSCUHMNNSA-N mesaconic acid Chemical compound OC(=O)C(/C)=C/C(O)=O HNEGQIOMVPPMNR-NSCUHMNNSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000001053 micromoulding Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000001259 photo etching Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 229940127558 rescue medication Drugs 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical class C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004441 surface measurement Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940052907 telazol Drugs 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 1
- 210000000836 trigeminal nuclei Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
- 229940032196 zolmitriptan 2.5 mg oral tablet Drugs 0.000 description 1
- 229940112955 zolmitriptan nasal spray Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3223555A CA3223555A1 (fr) | 2017-08-23 | 2017-08-23 | Procede d'obtention rapide de concentrations therapeutiques de zolmitriptan pour le traitement de migraines et de cephalees de horton |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3223555A CA3223555A1 (fr) | 2017-08-23 | 2017-08-23 | Procede d'obtention rapide de concentrations therapeutiques de zolmitriptan pour le traitement de migraines et de cephalees de horton |
| CA3073442A CA3073442C (fr) | 2017-08-23 | 2017-08-23 | Procede d'obtention rapide de concentrations therapeutiques de zolmitriptan pour le traitement de migraines et de cephalees de horton |
| PCT/US2017/048258 WO2019040063A1 (fr) | 2017-08-23 | 2017-08-23 | Procédé d'obtention rapide de concentrations thérapeutiques de zolmitriptan pour le traitement de migraines et de céphalées de horton |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3073442A Division CA3073442C (fr) | 2017-08-23 | 2017-08-23 | Procede d'obtention rapide de concentrations therapeutiques de zolmitriptan pour le traitement de migraines et de cephalees de horton |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3223555A1 true CA3223555A1 (fr) | 2019-02-28 |
Family
ID=59829462
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3223555A Pending CA3223555A1 (fr) | 2017-08-23 | 2017-08-23 | Procede d'obtention rapide de concentrations therapeutiques de zolmitriptan pour le traitement de migraines et de cephalees de horton |
| CA3073442A Active CA3073442C (fr) | 2017-08-23 | 2017-08-23 | Procede d'obtention rapide de concentrations therapeutiques de zolmitriptan pour le traitement de migraines et de cephalees de horton |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3073442A Active CA3073442C (fr) | 2017-08-23 | 2017-08-23 | Procede d'obtention rapide de concentrations therapeutiques de zolmitriptan pour le traitement de migraines et de cephalees de horton |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3672570A1 (fr) |
| JP (2) | JP7219384B2 (fr) |
| KR (2) | KR20210155817A (fr) |
| CN (1) | CN111050749A (fr) |
| AU (1) | AU2017428907B2 (fr) |
| CA (2) | CA3223555A1 (fr) |
| IL (1) | IL272776B1 (fr) |
| WO (1) | WO2019040063A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017143345A1 (fr) | 2016-02-19 | 2017-08-24 | Zp Opco, Inc. | Procédé pour obtenir rapidement des concentrations thérapeutiques de triptans pour le traitement de migraines |
| US11660264B2 (en) | 2017-08-23 | 2023-05-30 | Emergex USA Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
| US11660265B2 (en) | 2018-06-28 | 2023-05-30 | Emergex USA Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
| WO2020245667A1 (fr) * | 2019-06-06 | 2020-12-10 | Kindeva Drug Delivery L.P. | Support de microréseau destiné à un applicateur de microréseau |
| KR20220053554A (ko) * | 2019-06-28 | 2022-04-29 | 패스포트 테크놀로지스, 인크. | 트립탄 미세천공 전달 시스템 |
| CN114699510A (zh) * | 2021-12-29 | 2022-07-05 | 浙江湃肽生物有限公司 | 一种司美格鲁肽微针阵列及其制备方法 |
| CN115887903A (zh) * | 2022-12-15 | 2023-04-04 | 太平洋康泰科学仪器（济南）有限公司 | 微针贴片给药组件及给药方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5147296A (en) | 1988-10-03 | 1992-09-15 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5169382A (en) | 1988-10-03 | 1992-12-08 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| WO1997048440A1 (fr) | 1996-06-18 | 1997-12-24 | Alza Corporation | Dispositif d'amelioration d'apport ou d'echantillonnage d'agents transdermiques |
| US5738728A (en) | 1996-07-26 | 1998-04-14 | Bio Dot, Inc. | Precision metered aerosol dispensing apparatus |
| US5743960A (en) | 1996-07-26 | 1998-04-28 | Bio-Dot, Inc. | Precision metered solenoid valve dispenser |
| US5916524A (en) | 1997-07-23 | 1999-06-29 | Bio-Dot, Inc. | Dispensing apparatus having improved dynamic range |
| US5741554A (en) | 1996-07-26 | 1998-04-21 | Bio Dot, Inc. | Method of dispensing a liquid reagent |
| KR100572539B1 (ko) | 1997-12-11 | 2006-04-24 | 알자 코포레이션 | 경피성 작용제 유동률을 증진시키기 위한 장치 |
| KR100557261B1 (ko) | 1997-12-11 | 2006-03-07 | 알자 코포레이션 | 경피성 작용제 유동률을 증진시키기 위한 장치 |
| KR100561892B1 (ko) | 1997-12-11 | 2006-03-16 | 알자 코포레이션 | 경피성 작용제 유동률을 증진시키기 위한 장치 |
| US6091975A (en) | 1998-04-01 | 2000-07-18 | Alza Corporation | Minimally invasive detecting device |
| ATE310561T1 (de) | 1999-12-10 | 2005-12-15 | Alza Corp | Vorrichtung und verfahren zur verbesserung des mikronadel-haut-piercing |
| JP4104975B2 (ja) | 2000-10-13 | 2008-06-18 | アルザ・コーポレーシヨン | 衝撃適用装置用の微小突起部材保持器 |
| US7419481B2 (en) | 2000-10-13 | 2008-09-02 | Alza Corporation | Apparatus and method for piercing skin with microprotrusions |
| ES2324461T3 (es) | 2000-10-13 | 2009-08-07 | Alza Corporation | Aparato y procedimiento para perforar la piel con microprotuberancias. |
| ES2243564T3 (es) | 2000-10-13 | 2005-12-01 | Alza Corporation | Aplicador de red de microlamas que produce un impacto. |
| RU2282468C2 (ru) | 2000-10-26 | 2006-08-27 | Алза Корпорейшн | Устройство для трансдермальной доставки лекарственных средств, имеющее микровыступы с покрытием |
| WO2002074173A1 (fr) | 2001-03-16 | 2002-09-26 | Alza Corporation | Procede et appareil de revetement de microprojections de perçage de peau |
| MXPA03009603A (es) | 2001-04-20 | 2004-12-06 | Johnson & Johnson | Arreglo de microproyeccion que tiene un agente benefico que contiene un recubrimiento. |
| WO2005044333A2 (fr) | 2003-10-31 | 2005-05-19 | Alza Corporation | Applicateur a actionnement automatique pour reseau de micro-protuberances |
| AU2005244734A1 (en) | 2004-05-13 | 2005-12-01 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents |
| CN101466393A (zh) | 2006-03-15 | 2009-06-24 | 阿尔扎公司 | 用于经皮递送甲状旁腺激素药剂以治疗骨质减少的方法 |
| WO2008115586A1 (fr) * | 2007-03-21 | 2008-09-25 | Alza Corporation | Appareil et procédé d'administration transdermique d'un agoniste de triptane |
| JP6121734B2 (ja) * | 2012-02-09 | 2017-04-26 | 久光製薬株式会社 | マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス |
| US20150038897A1 (en) | 2013-07-30 | 2015-02-05 | Zosano Pharma, Inc. | Low-Profile Microneedle Patch Applicator |
| WO2017143345A1 (fr) * | 2016-02-19 | 2017-08-24 | Zp Opco, Inc. | Procédé pour obtenir rapidement des concentrations thérapeutiques de triptans pour le traitement de migraines |
-
2017
- 2017-08-23 EP EP17764703.9A patent/EP3672570A1/fr active Pending
- 2017-08-23 CA CA3223555A patent/CA3223555A1/fr active Pending
- 2017-08-23 KR KR1020217040858A patent/KR20210155817A/ko active IP Right Grant
- 2017-08-23 JP JP2020532539A patent/JP7219384B2/ja active Active
- 2017-08-23 CN CN201780094159.6A patent/CN111050749A/zh active Pending
- 2017-08-23 KR KR1020207005263A patent/KR102340393B1/ko active IP Right Grant
- 2017-08-23 AU AU2017428907A patent/AU2017428907B2/en not_active Expired - Fee Related
- 2017-08-23 CA CA3073442A patent/CA3073442C/fr active Active
- 2017-08-23 IL IL272776A patent/IL272776B1/en unknown
- 2017-08-23 WO PCT/US2017/048258 patent/WO2019040063A1/fr unknown
-
2023
- 2023-01-05 JP JP2023000670A patent/JP2023033378A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3073442C (fr) | 2024-02-06 |
| JP7219384B2 (ja) | 2023-02-08 |
| JP2023033378A (ja) | 2023-03-10 |
| IL272776B1 (en) | 2024-02-01 |
| IL272776A (en) | 2020-04-30 |
| AU2017428907A1 (en) | 2020-03-05 |
| KR20200032170A (ko) | 2020-03-25 |
| AU2017428907B2 (en) | 2021-12-16 |
| CN111050749A (zh) | 2020-04-21 |
| JP2021500397A (ja) | 2021-01-07 |
| KR102340393B1 (ko) | 2021-12-17 |
| KR20210155817A (ko) | 2021-12-23 |
| EP3672570A1 (fr) | 2020-07-01 |
| WO2019040063A1 (fr) | 2019-02-28 |
| CA3073442A1 (fr) | 2019-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3073442C (fr) | Procede d'obtention rapide de concentrations therapeutiques de zolmitriptan pour le traitement de migraines et de cephalees de horton | |
| US11660264B2 (en) | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches | |
| US11839683B2 (en) | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines | |
| RU2282468C2 (ru) | Устройство для трансдермальной доставки лекарственных средств, имеющее микровыступы с покрытием | |
| US20040138610A1 (en) | Active agent delivery device having composite members | |
| EP2005990A2 (fr) | Appareil à micro-aiguilles et appareil d'administration transdermique à micro-aiguilles | |
| US20230210762A1 (en) | Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions | |
| US11660265B2 (en) | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches | |
| US7455654B2 (en) | Method and apparatus for reducing the incidence of tobacco use | |
| JP2009542657A (ja) | ゲルの形態でのロピニロール含有薬学的組成物、その使用 | |
| WO2008115586A1 (fr) | Appareil et procédé d'administration transdermique d'un agoniste de triptane | |
| US20230255881A1 (en) | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231218 |
|
| EEER | Examination request |
Effective date: 20231218 |
|
| EEER | Examination request |
Effective date: 20231218 |
|
| EEER | Examination request |
Effective date: 20231218 |